Clinical Trial Search

Primary: Phase 1b: Number of Participants Experiencing at Least One Dose Limiting Toxicity (DLT) — 0; 0 Participants

Primary: Change in Streptococcus Mutans Levels in Dental Plaque — 3.11; 0.93; 1.91; 2.23 log10CFU/g — p=0.123

Primary: Part A: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 — 10; 19; 9; 0…

Primary: Energy Expenditure — 1.37; 1.40; 1.28; 1.27 kcal/min — p=0.0001

Primary: Maximum Tolerated Dose of Radiosurgery — 48; 60 Gy

Primary: Number of Subjects With Pregnancy Outcomes to Measure Contraceptive Efficacy — 100 Participants

Primary: Inter-rater Agreement of the International Federation of Clinical Neurophysiology (IFCN) Criteria (Cut-off=4) in Sensor Space and of Detection of Epileptiform Discharges…

Primary: Number of Participant With Decrease in Direct Bilirubin Level — 2; 0 Participants

Primary: Tolerability of Nilotinib Over Placebo — 21; 19; 20 Participants — p=0.3626

Primary: Number of Participants With Unscheduled Return to Clinic or Emergency Room — 8; 1 Participants

Primary: Number of Treatment Related Adverse Events — 27; 37; 41; 46 Adverse Events

Primary: Number of Participants With a Clinical Response at Week 8 — 33; 45; 30 Participants

Primary: Immunogenicity Endpoint: The Geometric Mean Titer (GMT) and GMT Ratio for the Four Strains Included in the Vaccine, Non-inferiority Analysis. — 65.01; NA; NA; 75.16…

Primary: The Number of Subjects With Treatment-related Adverse Events (TEAEs) and the Number of TEAEs Will be Summarized Using Frequency Counts (Safety and Tolerability) — 0; 0…

Primary: Operative Time — 46; 43 minutes